Clinical trial · Interventional
A Randomized Phase II Study of Concurrent Chemoradiation With Every 3 Week of Cisplatin vs With Weekly Cisplatin in Locally Advanced Nasopharyngeal Carcinoma
NCT01171781CI-TRIAL-00003721unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study try to show the weekly cisplatin based CCRT is not inferior to 3-weekly cisplabe based CCRT in terms of 3-yr progression free survival rate in advanced nasopharyngeal carcinoma
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nasophayngeal Carcinoma Between Stage II and IVb | — | UNRESOLVED | — |
Interventions
Interventions (2)
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- 3 weekly CDDP based CCRT
- description
- radiation (conventioal or IMRT) with 3 cycles of 3-weekly cisplatin
- interventionNames
- Drug: cisplatin (3 weekly)
- type
- EXPERIMENTAL
- label
- weekly cisplatin based CCRT
- description
- radiation (conventional or IMRT) with 7 cycles of weekly cisplatin therapy
- interventionNames
- Drug: cisplatin (weekly)
Primary outcomes (1)
- measure
- progression free survival rate at 3 years
- timeFrame
- 36 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * histologically confirmed nasopharyngeal carcinoma age of 18 years or over stage II \~ IVb no history of chemotherapy, radiotherapy, or immunotherapy for NPC with measurable lesion based on RECIST 1.1 ECOG PS 0 \~2 good organ function (liver, renal, hematologic) Exclusion Criteria: * active infectious disease requiring antibiotics uncontrolled heart disease pregnancy and on feeding state history of other malignancy within 5 years before enrollment, except for well treated non-melanomatous skin cancer, in situ cervical cancer, thyroid cancer
References
Publications (0)
Data not yet available
No reference posted for this study.